# Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

> **NCT06078839** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Xu Li** · enrollment: 778 (estimated)

## Conditions studied

- Sepsis
- Sepsis-induced Coagulopathy
- Nafamostat Mesilate

## Interventions

- **DRUG:** Nafamostat mesilate
- **DRUG:** 5% glucose

## Key facts

- **NCT ID:** NCT06078839
- **Lead sponsor:** Xu Li
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 778 (ESTIMATED)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06078839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06078839, "Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06078839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*